Theravance Biopharma(NASDAQ) TBPH

Theravance Biopharma, Inc. makes medicines for lung and nerve problems. One drug helps people with chronic lung disease breathe easier. Another project focuses on a rare disorder affecting blood pressure.

Medicines for Easier Breathing

• Respiratory Treatment: YUPELRI inhalation solution for the maintenance treatment of chronic obstructive pulmonary disease (COPD), a condition that makes breathing difficult.
• Nerve System Research: Ampreloxetine, an experimental drug for a rare condition called multiple system atrophy that causes low blood pressure upon standing.
• Royalty Rights: Financial interests in TRELEGY, a combination inhaler used for both asthma and COPD.

A New Path Forward

• Agreed to be acquired by Zymeworks in June 2026 for $17.00 per share plus a contingent value right.
• Secured regulatory approval for YUPELRI in China in June 2025 through a partnership with Viatris.
• Sold future royalty rights for TRELEGY to GSK in June 2025 for $225.0 million.
• Launched an organizational restructuring in March 2026 to focus on commercial operations and reduce costs.

How the Business Competes

Theravance Biopharma uses a profit-sharing model for its flagship lung medicine to reach patients across the U.S. and China. The company maintains a lean operational structure by focusing on late-stage development and strategic partnerships with larger pharmaceutical firms.

Vital Signs and Statistics

• Cash, cash equivalents, and marketable securities totaled $387.7 million as of June 30, 2026.
• Revenue from the Viatris collaboration was $20.7 million in the second quarter of 2026, up 11% year over year.
• Restructuring efforts are expected to save approximately $70 million in annual costs starting in the second half of 2026.
• The company received a $50.0 million milestone payment for TRELEGY sales performance in Feb. 2026.
• Research and development (R&D) expenses fell 55% to $4.7 million in the three-month period ended June 30, 2026.

Final Overview

Theravance Biopharma has transitioned from a research organization to a focused commercial entity preparing for a merger. Its strategy combines stable revenue from lung treatments with potential payments from future drug milestones.